The present invention offers an innovative method of purifying glial progenitor cells highly biased to oligodendrocyte fate. The cells are less prone to both rejection and local graft vs. host injury after allogeneic transplant.
These cells may be obtained from adult human brain, and human ES cell cultures, etc. These cells will be used for cell transplantation-based therapy of both pediatric and adult dysmyelinating and demyelinating diseases.
Currently available oligodentrocyte progenitor cell preparations are based entirely on A2B5 expression, and as such do not exclude 1) multipotential progenitors, 2) astrocyte-biased progenitors; 3) fibrous astrocytes; 4) neuronal progenitors; and 5) microglial cells. The invention describes the isolation of a more discrete, better antigenically defined population that is free of all of these contaminating neural phenotypes, and hence yields more predictable, higher efficiency oligodendrocyte differentiation and remyelination than any human cellular vector yet described, with less likelihood of rejection.
URV Reference Number: 6-1599